What's on this Page
Dexrazoxane Brand Names- Totect | Zinecard
What is Dexrazoxane
Dexrazoxane is a cytoprotective agent. It is used to reduce the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control.
It is also used for the treatment of extravasation resulting from intravenous anthracycline chemotherapy.
Dexrazoxane may increase the myelosuppressive effects of chemotherapeutic agents; hematologic monitoring is recommended.
Indications
- anthracycline-induced cardiomyopathy prophylaxis
- extravasation
For anthracycline-induced cardiomyopathy prophylaxis
NOTE: Dexrazoxane has been designated an orphan drug by the FDA for the prevention of cardiomyopathy associated with doxorubicin administration.
in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who may benefit from continued doxorubicin therapy
Side Effects
- abdominal pain
- alopecia
- anaphylactoid reactions
- anemia
- angioedema
- anorexia
- bleeding
- bronchospasm
- cardiotoxicity
- constipation
- cough
- depression
- diarrhea
- dizziness
- dyspnea
- elevated hepatic enzymes
- elevated hepatic enzymes
- erythema
- fatigue
- fever
- headache
- hyperbilirubinemia
- hyperbilirubinemia
- hypercalcemia
- hypercalcemia
- hyponatremia
- hypotension
- infection
- injection site reaction
- insomnia
- leukopenia
- leukopenia
- malaise
- nausea
- nephrotoxicity
- neurotoxicity
- neutropenia
- neutropenia
- new primary malignancy
- peripheral edema
- phlebitis
- radiation recall reaction
- thrombocytopenia
- thrombocytopenia
- urticaria
- vomiting
Monitoring Parameters
- CBC
- LFTs
- serum creatinine/BUN
Contraindications
- bone marrow suppression
- breast-feeding
- contraception requirements
- hepatic disease
- infertility
- male-mediated teratogenicity
- pregnancy
- renal impairment
- reproductive risk
Interactions
- Doxorubicin
Doxorubicin: (Moderate) Dexrazoxane is a cardioprotectant administered prior to doxorubicin-containing chemotherapy regimens in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy.
Monitor blood counts if these agents are used together; additive myelosuppression may occur. Do not use dexrazoxane as a cardioprotectant when doxorubicin therapy is first begun; significantly lower tumor response rates and a shorter time to disease progression were reported in women with metastatic breast cancer who received dexrazoxane at the start of doxorubicin therapy in a randomized trial.
